全文获取类型
收费全文 | 4883篇 |
免费 | 546篇 |
国内免费 | 4篇 |
专业分类
耳鼻咽喉 | 37篇 |
儿科学 | 111篇 |
妇产科学 | 144篇 |
基础医学 | 740篇 |
口腔科学 | 35篇 |
临床医学 | 493篇 |
内科学 | 1093篇 |
皮肤病学 | 174篇 |
神经病学 | 422篇 |
特种医学 | 225篇 |
外科学 | 624篇 |
综合类 | 33篇 |
一般理论 | 2篇 |
预防医学 | 404篇 |
眼科学 | 59篇 |
药学 | 176篇 |
中国医学 | 3篇 |
肿瘤学 | 658篇 |
出版年
2022年 | 40篇 |
2021年 | 102篇 |
2020年 | 56篇 |
2019年 | 89篇 |
2018年 | 65篇 |
2017年 | 91篇 |
2016年 | 75篇 |
2015年 | 100篇 |
2014年 | 138篇 |
2013年 | 154篇 |
2012年 | 239篇 |
2011年 | 250篇 |
2010年 | 148篇 |
2009年 | 136篇 |
2008年 | 189篇 |
2007年 | 217篇 |
2006年 | 230篇 |
2005年 | 223篇 |
2004年 | 238篇 |
2003年 | 223篇 |
2002年 | 199篇 |
2001年 | 196篇 |
2000年 | 203篇 |
1999年 | 154篇 |
1998年 | 72篇 |
1997年 | 47篇 |
1996年 | 45篇 |
1995年 | 31篇 |
1994年 | 32篇 |
1993年 | 41篇 |
1992年 | 114篇 |
1991年 | 110篇 |
1990年 | 93篇 |
1989年 | 102篇 |
1988年 | 100篇 |
1987年 | 88篇 |
1986年 | 100篇 |
1985年 | 71篇 |
1984年 | 61篇 |
1983年 | 57篇 |
1982年 | 49篇 |
1981年 | 24篇 |
1980年 | 27篇 |
1979年 | 46篇 |
1978年 | 39篇 |
1976年 | 28篇 |
1975年 | 36篇 |
1974年 | 33篇 |
1973年 | 25篇 |
1971年 | 24篇 |
排序方式: 共有5433条查询结果,搜索用时 15 毫秒
101.
MJ Stevens PD Stricker J Saalfeld PC Brenner R Kooner GFA O'Neill PJ Duval RS Jagavkar P Cross J Martland 《Journal of Medical Imaging and Radiation Oncology》2003,47(2):152-160
Combination high dose rate brachytherapy (HDRB) and external beam radiation therapy is technically and clinically feasible as definitive treatment for localized prostate cancer. We report the first large Australian experience using this technique of radiation dose escalation in 82 patients with intermediate‐ and high‐risk disease. With a median follow up of 3 years (156 weeks), complications were low and overall prostate‐specific antigen progression‐free survival was 91% using the American Society for Therapeutic Radiology and Oncology consensus definition. The delivery of hypofractionated radiation through the HDRB component shortens overall treatment time and is both biologically and logistically advantageous. As a radiation boost strategy, HDRB is easy to learn and could be introduced into most facilities with brachytherapy capability. 相似文献
102.
OBJECTIVE: Many new stool tests intended to detect neoplastic cells or cell products are developed at present for colorectal cancer (CRC) screening. The aim of this study was to simulate a population-based screening setting to assess and compare the potential for early detection and prevention of CRC of screening based on stool tests with different sensitivity and specificity and of screening with colonoscopy as a primary screening tool. METHOD: A Markov model was developed aimed to estimate the proportion of CRC cases which are early detected or prevented due to screening as well as the number of equired stool tests and colonoscopies per early detected or prevented CRC case. Model outcomes were calculated for the offer of annual stool testing from age 55 to 74 in combination with colonoscopic follow-up of positive test results and for the offer of screening colonoscopy as a primary screening tool at ages 55 and 65. The long-lasting risk reduction of colonoscopy allowing the removal of precancerous lesions was taken into account quantitatively. RESULTS: For a variety of stool tests with different performance characteristics, the proportion of CRC cases early detected or prevented was estimated to be higher for stool testing in combination with colonoscopic follow-up of positive test results compared with screening colonoscopy assuming levels of compliance to be expected for the respective screening scheme. Optimizing performance characteristics of stool tests in terms of detecting precancerous lesions, in addition to those in terms of detecting CRC, seemed to be crucial for maximizing effectiveness of CRC screening with stool tests. CONCLUSION: Screening based on new stool tests with colonoscopic follow-up of positive test results might offer a high potential for early detection or prevention of CRC. 相似文献
103.
BACKGROUND: Over the last decades, long-term survival rates have substantially increased for many forms of cancer. However, these improvements have often been detected with substantial delay by traditional methods of survival analyses. PATIENTS AND METHODS: Using data of the population-based Saarland Cancer Registry, 5- and 10-year relative survival rates were derived for patients with 24 common forms of cancer in Saarland/Germany for the years 2000-2002 by period analysis and compared with conventional cohort estimates of 5- and 10-year relative survival rates pertaining to patients diagnosed in 1990-1992. RESULTS: For many forms of cancer, the 2000-2002 period survival estimates were substantially higher than the corresponding estimates for the cohorts of patients diagnosed in 1990-1992. For example, 10-year relative survival rates achieved in 2000-2002 were close to 100% for patients with testis and thyroid cancer, >85% for patients with melanomas of the skin, approximately 80% for patients with endometrial cancer and prostate cancer, close to 70% for patients with breast cancer and kidney cancer, and close to 60% for patients with colon cancer and lymphomas. CONCLUSIONS: Survival expectations of patients diagnosed with cancer at the beginning of the third millenium are substantially higher than previously available survival statistics have suggested. 相似文献
104.
H Brenner V Arndt C Stegmaier H Ziegler T Stürmer 《European journal of cancer prevention》2005,14(3):231-237
Endoscopic screening (sigmoidoscopy, colonoscopy) with removal of precancerous lesions can prevent a large proportion of colorectal cancers (CRCs). However, there is lack of data regarding optimal age, time intervals and numbers of screening examinations. We developed and applied modified techniques of epidemiological analysis to evaluate the impact of various endoscopy-based screening strategies on prevention of clinically manifest CRCs between the ages of 50 and 79 in a population-based case-control study (294 cases, 254 controls) conducted in Saarland, Germany. We found a strong potential for reduction of CRC occurrence even with a single screening endoscopy. The optimal age for a single screening endoscopy appears to be around 55 (estimated potential for prevention of cases between the ages of 55 and 79 in case of 100% compliance: 77% (95% confidence interval (CI) 46-90%)). A single screening endoscopy at age 50 would have a lower impact due to failure to prevent CRC at higher ages. Similarly, screening at ages 60 or older would have a lower impact because it would fail to prevent CRC at lower ages. Repeated offers of screening examinations could provide substantial additional benefit with the levels of compliance to be expected in practice, but they would have to be weighed against the increased risks and costs. 相似文献
105.
L. Kurch D. Hasenclever R. Kluge T. Georgi L. Tchavdarova M. Golombeck O. Sabri A. Eggert W. Brenner K.W. Sykora F.M. Bengel C. Rossig D. Krholz M. Schfers T. Feuchtinger P. Bartenstein R.A. Ammann T. Krause C. Urban R. Aigner S. Gattenlhner W. Klapper C. Mauz‐Krholz 《Pediatric blood & cancer》2019,66(3)
106.
Inherited variation in circadian rhythm genes and risks of prostate cancer and three other cancer sites in combined cancer consortia 下载免费PDF全文
Fangyi Gu Han Zhang Paula L. Hyland Sonja Berndt Susan M. Gapstur William Wheeler the ELLIPSE consortium Christopher I. Amos Stephane Bezieau Heike Bickeb?ller Hermann Brenner Paul Brennan Jenny Chang‐Claude David V Conti Jennifer Anne Doherty Stephen B Gruber Tabitha A Harrison Richard B Hayes Michael Hoffmeister Richard S Houlston Rayjean J. Hung Mark A. Jenkins Peter Kraft Kate Lawrenson James McKay Sarah Markt Lorelei Mucci Catherine M. Phelan Conghui Qu Angela Risch Mary Anne Rossing H.‐Erich Wichmann Jianxin Shi Eva Schernhammer Kai Yu Maria Teresa Landi Neil E. Caporaso 《International journal of cancer. Journal international du cancer》2017,141(9):1794-1802
Circadian disruption has been linked to carcinogenesis in animal models, but the evidence in humans is inconclusive. Genetic variation in circadian rhythm genes provides a tool to investigate such associations. We examined associations of genetic variation in nine core circadian rhythm genes and six melatonin pathway genes with risk of colorectal, lung, ovarian and prostate cancers using data from the Genetic Associations and Mechanisms in Oncology (GAME‐ON) network. The major results for prostate cancer were replicated in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial, and for colorectal cancer in the Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO). The total number of cancer cases and controls was 15,838/18,159 for colorectal, 14,818/14,227 for prostate, 12,537/17,285 for lung and 4,369/9,123 for ovary. For each cancer site, we conducted gene‐based and pathway‐based analyses by applying the summary‐based Adaptive Rank Truncated Product method (sARTP) on the summary association statistics for each SNP within the candidate gene regions. Aggregate genetic variation in circadian rhythm and melatonin pathways were significantly associated with the risk of prostate cancer in data combining GAME‐ON and PLCO, after Bonferroni correction (ppathway < 0.00625). The two most significant genes were NPAS2 (pgene = 0.0062) and AANAT (pgene = 0.00078); the latter being significant after Bonferroni correction. For colorectal cancer, we observed a suggestive association with the circadian rhythm pathway in GAME‐ON (ppathway = 0.021); this association was not confirmed in GECCO (ppathway = 0.76) or the combined data (ppathway = 0.17). No significant association was observed for ovarian and lung cancer. These findings support a potential role for circadian rhythm and melatonin pathways in prostate carcinogenesis. Further functional studies are needed to better understand the underlying biologic mechanisms. 相似文献
107.
Cecilia Becattini Rupert Bauersachs Giorgio Maraziti Laurent Bertoletti Alexander Cohen Jean M. Connors Dario Manfellotto Antonio Sanchez Benjamin Brenner Giancarlo Agnelli 《Haematologica》2022,107(7):1567
The effect of renal impairment (RI) on risk of bleeding and recurrent thrombosis in cancer patients treated with direct oral anticoagulants for venous thromboembolism (VTE) is undefined. We ran a prespecified analysis of the randomized Caravaggio study to evaluate the role of RI as a risk factor for bleeding or recurrence in patients treated with dalteparin or apixaban for cancer-associated VTE. RI was graded as moderate (creatinine clearance between 30-59 mL/minute; 275 patients) and mild (between 60-89 mL/minute; 444 patients). In the 1142 patients included in this analysis, the incidence of major bleeding was similar in patients with moderate vs. no or mild RI (HR 1.06-95% CI: 0.53-2.11), with no difference in the relative safety of apixaban and dalteparin. Recurrent VTE was not different in moderate vs. no or mild RI (HR=0.67, 95% CI: 0.38-1.20); in moderate RI, apixaban reduced recurrent VTE compared to dalteparin (HR=0.27, 95% CI: 0.08-0.96; P for interaction 0.1085). At multivariate analysis, no association was found between variation of renal function over time and major bleeding or recurrent VTE. Advanced or metastatic cancer was the only independent predictor of major bleeding (HR=2.84, 95% CI: 1.20-6.71), with no effect of treatment with apixaban or dalteparin. In our study, in cancer patients treated with apixaban or dalteparin, moderate RI was not associated with major bleeding or recurrent VTE. In patients with moderate renal failure, the safety profile of apixaban was confirmed with the potential for improved efficacy in comparison to dalteparin. ClinicalTrials.gov identifier: . NCT03045406相似文献
108.
109.
110.
F.T. Brenner 《American journal of surgery》1943,59(1):141-142